MIND MEDICINE (MINDMED) INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.25 USD | +0.49% |
|
-17.61% | +98.09% |
| Jun. 05 | Sector Update: Health Care Stocks Steady Premarket Wednesday | MT |
| Jun. 05 | Mind Medicine Shares Fall After FDA Committee Votes Against Lykos Therapeutics' Psychedelic Drug | MT |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 521M |
|---|---|---|---|---|---|
| Net income 2024 * | -124M | Net income 2025 * | -106M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 185M | Net cash position 2025 * | 100M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-3.98
x | P/E ratio 2025 * |
-5.13
x | Employees | 57 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.33% |
More Fundamentals
* Assessed data
More news
Latest transcript on Mind Medicine (MindMed) Inc.
More recommendations
More press releases
More news
| 1 day | +0.49% | ||
| 1 week | -17.61% | ||
| Current month | -17.61% | ||
| 1 month | -20.50% | ||
| 3 months | -25.26% | ||
| 6 months | +125.86% | ||
| Current year | +98.09% |
1 week
6.60
8.65
1 month
6.609.55
Current year
3.4912.22
1 year
2.4112.22
3 years
2.1260.60
5 years
1.2586.55
10 years
1.2586.55
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Barrow
CEO | Chief Executive Officer | 35 | 21-01-13 |
Miri Wernli
PSD | President | 71 | 20-02-27 |
Daniel Karlin
CTO | Chief Tech/Sci/R&D Officer | 44 | 21-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Andreas Krebs
BRD | Director/Board Member | 65 | 21-09-28 |
Suzanne Bruhn
BRD | Director/Board Member | 60 | 22-08-10 |
David Gryska
BRD | Director/Board Member | 68 | 23-06-20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 7.25 | +0.49% | 1,188,060 |
| 24-06-06 | 7.215 | -2.76% | 1,757,512 |
| 24-06-05 | 7.42 | -10.06% | 5,481,261 |
| 24-06-04 | 8.25 | -4.73% | 1,525,961 |
| 24-06-03 | 8.66 | -1.59% | 1,090,064 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotes
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
Calendar
10:00am
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
7.25
USD
Average target price
24.25
USD
Spread / Average Target
+234.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +98.09% | 521M | |
| +51.85% | 57.87B | |
| +41.42% | 40.25B | |
| -5.25% | 39.94B | |
| -5.16% | 28.54B | |
| +12.79% | 26.4B | |
| -20.18% | 19.33B | |
| +30.88% | 12.4B | |
| +0.61% | 12.23B | |
| +25.06% | 12.2B |
- Stock Market
- Equities
- MNMD Stock
